- Condition: Alzheimer's Disease
Interventions: Drug: MABT5102A; Drug: MABT5102A; Drug: placebo; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified August 2011 - Condition: Dementia Alzheimer's Type
Interventions: Drug: SAR110894D; Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Mild Cognitive Impairment (MCI); Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); Northern California Institute for Research and Education (NCIRE); National Institute on Aging (NIA)
Recruiting - verified May 2012 - Condition: Alzheimer's Disease
Intervention: Drug: Solanezumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); Northern California Institute for Research and Education (NCIRE); National Institute on Aging (NIA)
Recruiting - verified February 2012 - Condition: Alzheimer Disease
Intervention: Drug: Bapineuzumab 0.5 mg/kg
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Alzheimer Disease
Intervention: Drug: ACC-001+ QS21
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified April 2012 - Condition: Alzheimer Disease
Intervention: Drug: bapineuzumab
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified March 2012 - Condition: Alzheimer's Disease
Intervention:
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Institute on Aging (NIA)
Recruiting - verified October 2011 - Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: bapineuzumab; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
 |
Join Clinical Trials in Rhode Island for Alzheimers Disease |
